In an open-label trial carried out on the northwest border of Thailand, 1596 patients with uncomplicated multidrug-resistant falciparum malaria were randomly assigned to receive atovaquone-proguanil, atovaquone-proguanil-artesunate, or artesunate-mefloquine and were followed up for 42 days. All 3 regimens were highly effective and well tolerated. Fever duration and parasite clearance times were significantly shorter among patients who received artesunate (P<.001). Polymerase chain reaction genotyping confirmed that recrudescence occurred in 13 patients who received artesunate-mefloquine (2.4%), 5 who received atovaquone-proguanil-artesunate (0.9%), and 15 who received atovaquone-proguanil (2.8%). Adding artesunate to atovaquone-proguanil reduced the risk of failure 3-fold (95% confidence interval [CI], 1.1-8.2) and subsequent gametocyte carriage 21-fold (95% CI, 14-30). Gastrointestinal complaints in the first 48 h after initiation of treatment were more common among artesunate recipients, but after day 2, dizziness, sleep disturbance, nausea, vomiting, and anorexia were more common among mefloquine recipients (P< or =.014). Artesunate-atovaquone-proguanil is a highly effective and well-tolerated treatment for multidrug-resistant falciparum malaria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/344901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review.
Ann Pharmacother
December 2024
Department of Pharmacy Practice, ETSU Bill Gatton College of Pharmacy, East Tennessee State University, Johnson City, TN, USA.
Article Synopsis
- - The review highlights the efficacy and safety of pivmecillinam in treating uncomplicated acute cystitis, based on data from six randomized controlled trials showing effectiveness at doses of 200 to 400 mg taken three times daily for 3 to 7 days.
- - Higher doses (400 mg) and longer treatment durations resulted in better clinical and bacteriologic outcomes, while pivmecillinam is particularly beneficial for populations not commonly approved by the FDA, like men or pregnant women.
- - As antibiotic resistance increases, pivmecillinam offers a new, potentially effective outpatient treatment option for uncomplicated acute cystitis in the U.S., with a focus on cost and its low resistance profile in managing uropathogens. *
A cynomolgus monkey urinary tract infection model confirms efficacy of new FimH vaccine candidates.
Infect Immun
October 2024
Pfizer Vaccine Research and Development, Pearl River, New York, USA.
The increase in urinary tract infections (UTI) caused by antibiotic-resistant requires the development of new therapeutic agents and prophylactic vaccines. To evaluate the efficacy of new lead candidates, we implemented a cynomolgus macaque UTI challenge model that mimics human uncomplicated cystitis in response to transurethral challenge with a multidrug-resistant (MDR) serotype O25b ST131 isolate. fimbrial adhesin FimH and O-antigens are separately under clinical evaluation by others as vaccine candidates to prevent UTI and invasive urosepsis disease, respectively.
View Article and Find Full Text PDFThe Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review.
Indian J Microbiol
September 2024
Autonomous State Medical College, Lakhimpur Kheri, Uttar Pradesh India.
Article Synopsis
- The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens has severely limited treatment options for patients, prompting doctors to rely on older antibiotics like polymyxins and tetracyclines.
- Fosfomycin has gained attention for its effectiveness against both MDR and XDR bacteria, including gram-positive and gram-negative strains, as traditional antibiotics face increasing resistance.
- This review article evaluates fosfomycin's role in treating gram-negative infections, focusing on its mechanism, pharmacokinetics, clinical effectiveness, and resistance trends.
Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.
World J Urol
April 2024
Department of Urology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
Purpose: Fosfomycin has been used more frequently in managing uncomplicated urinary tract infections (UTIs) due to decreased compliance and increased multidrug-resistant bacteria. The aim of this network meta-analysis was to assess the efficacy of Fosfomycin compared to Nitrofurantoin, Trimethoprim-Sulfamethoxazole (TMP-SMX), and Ciprofloxacin in terms of clinical and microbiological cure alongside with other measurements.
Materials And Methods: We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL).
Comprehensive Review of Urinary Tract Infections in Renal Transplant Recipients: Clinical Insights and Management Strategies.
Cureus
February 2024
Medical Surgical Nursing, Smt. Radhikabai Meghe Memorial College of Nursing, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Urinary tract infections (UTIs) pose a significant challenge in the care of renal transplant recipients. This comprehensive review explores this population's multifaceted landscape of UTIs, emphasizing the importance of early diagnosis and tailored management strategies. Renal transplant recipients face an elevated risk of UTIs due to immunosuppression, altered urinary tract anatomy, and complex comorbidities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!